Foxp3-mediated Suppression of CD95L Expression Confers Resistance to Activation-induced Cell Death in Regulatory T Cells
Overview
Authors
Affiliations
CD4(+)CD25(++)Foxp3(+) regulatory T cells (Tregs) control self-reactive cells to maintain peripheral tolerance. Treg homeostasis has to be controlled tightly to ensure balanced Treg-mediated suppression. One mechanism that regulates the CD4(+) T cell pool is activation-induced cell death (AICD). This is mimicked in vitro by TCR restimulation-induced expression of the death ligand CD95L (FasL/APO-1L/CD178) in expanded T cells. These cells express the death receptor CD95 (Fas/APO-1), and binding of CD95L to CD95 results in AICD. In contrast, Tregs do not undergo AICD upon TCR (re)stimulation in vitro despite a functional CD95 cell death pathway. In this study, we show that human and murine Tregs express low levels of CD95L upon stimulation. Knockdown of the transcriptional repressor Foxp3 partially rescues CD95L expression and AICD in human Tregs. Moreover, upon stimulation Foxp3-mutant Tregs from Scurfy mice express CD95L similar to conventional T cells. We further addressed whether exogenous CD95 stimulation provides a mechanism of Treg homeostatic control in vivo in mice. Triggering of CD95 reduced Treg numbers systemically as reflected by in vivo imaging and decreased GFP(+) Treg numbers ex vivo. Our study reveals that Foxp3 negatively regulates CD95L expression in Tregs and demonstrates that Tregs are susceptible to homeostatic control by CD95 stimulation.
Mechanism and application of immune interventions in intracerebral haemorrhage.
Xu X, Li Y, Chen S, Wu X, Li J, Li G Expert Rev Mol Med. 2024; 26:e22.
PMID: 39375846 PMC: 11488334. DOI: 10.1017/erm.2024.22.
Ota T, Goto R, Harada T, Forgioni A, Kanazawa R, Ganchiku Y Immunohorizons. 2024; 8(4):295-306.
PMID: 38587418 PMC: 11066723. DOI: 10.4049/immunohorizons.2300117.
Molecular and temporal control of restimulation-induced cell death (RICD) in T lymphocytes.
Lee K, Epstein B, Lake C, Snow A Front Cell Death. 2023; 2.
PMID: 38074985 PMC: 10705843. DOI: 10.3389/fceld.2023.1281137.
Barnestein R, Galland L, Kalfeist L, Ghiringhelli F, Ladoire S, Limagne E Oncoimmunology. 2022; 11(1):2120676.
PMID: 36117524 PMC: 9481153. DOI: 10.1080/2162402X.2022.2120676.
Frutos-Rincon L, Gomez-Sanchez J, Inigo-Portugues A, Acosta M, Gallar J Int J Mol Sci. 2022; 23(6).
PMID: 35328417 PMC: 8951464. DOI: 10.3390/ijms23062997.